Azlocillin sodium salt

• CAT Number: A001200
• CAS Number: 37091-65-9
• Molecular Formula: C20H22N5O6S • Na
• Molecular Weight: 483.50
• Purity: ≥95%
• Storage: 3 years -20C powder
• IUPAC Name: sodium;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
• InChI: InChI=1S/C20H23N5O6S.Na/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30;/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29);/q;+1/p-1/t11-,12-,13+,16-;/m1./s1
• InChIKey: UVOCNBWUHNCKJM-XFAPPKAWSA-M
• SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)[O-])C.[Na+]

Azlocillin Sodium Salt（Cat No.:A001200）is a broad-spectrum penicillin antibiotic widely used in pharmaceutical and microbiological research. Effective against a variety of Gram-negative and Gram-positive bacteria, it is particularly useful for studying infections caused by Pseudomonas aeruginosa. Azlocillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, ultimately causing cell lysis. This compound is valued for investigating antibiotic resistance mechanisms, bacterial metabolism, and the development of new antibacterial therapies. Its sodium salt form enhances solubility, making Azlocillin Sodium Salt suitable for experimental applications requiring high aqueous stability and bioavailability.

Reference

1: Thomson R, Carter R, Gilpin C, Coulter C, Hargreaves M. Comparison of methods for processing drinking water samples for the isolation of Mycobacterium avium and Mycobacterium intracellulare. Appl Environ Microbiol. 2008 May;74(10):3094-8. doi: 10.1128/AEM.02009-07. Epub 2008 Mar 21. PubMed PMID: 18359837; PubMed Central PMCID: PMC2394917.2: Puiggròs Boldú S, Pujol Cubells M, Girona Brumós V, Prat Aixelà J, Muñoz Juncosa M. Stability study of azlocillin sodium in glass bottles and PVC bags containing intravenous admixtures. Boll Chim Farm. 1995 Sep;134(8):467-71. PubMed PMID: 7576447.3: Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. Am J Med. 1989 Nov 30;87(5A):123S-127S. PubMed PMID: 2589355.4: Matsen JM, Bosso JA. The use of aztreonam in the cystic fibrosis patient. Pediatr Infect Dis J. 1989 Sep;8(9 Suppl):S117-9; discussion S128-32. Review. PubMed PMID: 2682510.5: Bosso JA, Walker KB. Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis. Clin Pharm. 1988 Dec;7(12):897-901. PubMed PMID: 3208501.6: Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988 Mar;7(3):171-6. PubMed PMID: 3128767.7: Thompson DF, Stiles ML, Allen LV Jr, Tu YH. Compatibility of verapamil hydrochloride with penicillin admixtures during simulated Y-site injection. Am J Hosp Pharm. 1988 Jan;45(1):142-5. PubMed PMID: 3348228.8: Tartaglione TA, Nye L, Vishniavsky N, Poynor W, Polk RE. Multiple-dose pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers. Clin Pharm. 1986 Nov;5(11):911-6. PubMed PMID: 3780161.9: Pospisilová B, Simková M, Kubes J. [Conditions for the mercurimetric determination of the drug content of penicillins]. Pharmazie. 1986 Oct;41(10):705-8. German. PubMed PMID: 3823112.10: Woolf RA, Koup JR, Smith AL, Hilman BC, Goldmann D, Williams-Warren J. Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis. Clin Pharm. 1985 Nov-Dec;4(6):664-9. PubMed PMID: 4075734.11: Gundert-Remy U, Weber E. [Degradation of Azlocillin and Mezlocillin / I. Behaviour in biological material and buffer (author/’s transl)]. Arzneimittelforschung. 1981;31(12):2041-4. German. PubMed PMID: 6460506.12: Alfthan O, Renkonen OV, Ohlsson H. Treatment with azlocillin in complicated urinary tract infections. Arzneimittelforschung. 1979;29(12a):1979-81. PubMed PMID: 543906.13: Vent J. [Mezlocillin concentrations in human bone tissue]. Arzneimittelforschung. 1979;29(12a):1969-71. German. PubMed PMID: 543904.14: Bergan T, Michalsen H. Pharmacokinetics of azlocillin in children with cystic fibrosis. Arzneimittelforschung. 1979;29(12a):1955-7. PubMed PMID: 543899.15: Heimann G, von Heereman B, Gladtke E. [Pharmacokinetics of Azlocillin in premature and newborn infants (author/’s transl)]. Arzneimittelforschung. 1979;29(12a):1949-51. German. PubMed PMID: 543897.16: Gau W, Horster FA. [High pressure liquid chromatographic analysis of azlocillin and its penicilloate in urine]. Arzneimittelforschung. 1979;29(12a):1941-3. German. PubMed PMID: 543895.17: Soares LA, Trabulsi LR. Studies on the antibacterial activity of two new acylureidopenicillins, mezlocillin and azlocillin. Arzneimittelforschung. 1979;29(12a):1932-4. PubMed PMID: 543893.18: Daikos GK, Giamarellou H, Hadjipolydorou K, Kanellakopoulou K. Pseudomonas infections of the lung treated with azlocillin. Microbiology, pharmacokinetics, clinic. Arzneimittelforschung. 1979;29(12a):1976-8. PubMed PMID: 120747.19: Voigt WH, Metzger KG. [Ultrastructural and microbiological studies on the activity of azlocillin against Pseudomonas aeruginosa (author/’s transl)]. Arzneimittelforschung. 1979;29(12a):1937-9. German. PubMed PMID: 120746.20: Knothe H. [Antibacterial activity of mezlocillin and azlocillin/A survey (author/’s transl)]. Arzneimittelforschung. 1979;29(12a):1916-20. Review. German. PubMed PMID: 120745.